SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 86 filers reported holding SEELOS THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $410 | -85.1% | 2,226 | -3.1% | 0.00% | – |
Q2 2023 | $2,746 | +78.5% | 2,298 | +3.2% | 0.00% | – |
Q1 2023 | $1,538 | -76.8% | 2,226 | -77.2% | 0.00% | – |
Q4 2022 | $6,626 | -72.4% | 9,743 | -58.7% | 0.00% | – |
Q3 2022 | $24,000 | +1100.0% | 23,585 | +959.5% | 0.00% | – |
Q2 2022 | $2,000 | -33.3% | 2,226 | -39.9% | 0.00% | – |
Q1 2022 | $3,000 | -95.7% | 3,703 | -91.5% | 0.00% | – |
Q4 2021 | $70,000 | +900.0% | 43,540 | +1332.7% | 0.00% | – |
Q3 2021 | $7,000 | – | 3,039 | +7692.3% | 0.00% | – |
Q2 2021 | $0 | -100.0% | 39 | -99.5% | 0.00% | – |
Q1 2021 | $43,000 | – | 8,627 | +22020.5% | 0.00% | – |
Q4 2020 | $0 | – | 39 | +5.4% | 0.00% | – |
Q3 2020 | $0 | -100.0% | 37 | -99.0% | 0.00% | – |
Q2 2020 | $4,000 | -33.3% | 3,678 | -70.9% | 0.00% | – |
Q1 2020 | $6,000 | – | 12,650 | +1264900.0% | 0.00% | – |
Q4 2019 | $0 | – | 1 | 0.0% | 0.00% | – |
Q3 2019 | $0 | – | 1 | 0.0% | 0.00% | – |
Q2 2019 | $0 | -100.0% | 1 | -99.9% | 0.00% | – |
Q1 2019 | $3,000 | – | 953 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |